BioScience Managers appoints Elizabeth Klein Investment Consultant

Healthcare investment specialist BioScience Managers has appointed Elizabeth Klein as an Investment Consultant, to facilitate BioScience Managers’ UK investment deal flow, in particular to support its collaboration entered into in December 2016 with London-based investment firm Downing LLP.

Elizabeth Klein’s primary focus will be on sourcing and reviewing investment opportunities for BioScience Managers’ and the Downing FOUR Healthcare Share Class Venture Capital Trust (VCT).

BioScience Managers has more than 3 decades of investment experience in healthcare and life sciences, and operates a high value-add model, providing assistance and support to portfolio companies via a global team and international network of independent industry advisors.

Downing FOUR Healthcare is targeting £10 million for its allocation and anticipates investing between £0.5m to £1m per company alone or as part of a syndicate.

The focus is on organisations with clear technological and market advantages and near to mid-term commercialisation potential, across a wide spectrum of areas including therapeutics, medical devices, diagnostics and digital health.

Jeremy Curnock Cook, Managing Director of BioScience Managers, said: “We are delighted to welcome Liz to the BioScience Managers team. She is highly regarded and well connected in the UK life sciences sector and will provide excellent on-the-ground access to innovative investment opportunities, as we further expand our investment horizons.”

Klein said: “Whilst the UK is recognised globally for the strength of its science and medical innovation, it has not always had access to sufficient capital and expertise to succeed commercially. That has changed and VCTs are an important and tax-efficient part of the UK investment capital ecosystem.

 Given the backdrop of an ageing population and increasing global expenditure on healthcare, there are opportunities to find and fund innovative companies with the potential to deliver better healthcare for patients, improved efficiency for payors and attractive returns to investors.

Klein holds a first class degree in Applied Biology with Genetics, an MA in Medicine, Science and Society, and an MBA. During her career as a UK financial analyst she has worked at Dresdner Kleinwort, RW Baird, Bridgewell, Teathers and N+1 Singer.

She was the Starmine Healthcare Stockpicker of the year in 2006 and 2013. She established her own consultancy, Klein-Edmonds Associates in 2015 and alongside her role for BioScience Managers, she also provides consultancy to the UK BioIndustry Association (BIA) and Radnor Capital Partners, amongst others.